Theranostics,
Journal Year:
2020,
Volume and Issue:
11(2), P. 579 - 601
Published: Oct. 28, 2020
Current
cancer
therapies,
including
chemotherapy
and
radiotherapy,
are
imprecise,
non-specific,
often
administered
at
high
dosages
-
resulting
in
side
effects
that
severely
impact
the
patient's
overall
well-being.
A
variety
of
multifunctional,
cancer-targeted
nanotheranostic
systems
integrate
therapy,
imaging,
tumor
targeting
functionalities
a
single
platform
have
been
developed
to
overcome
shortcomings
traditional
drugs.
Among
imaging
modalities
used,
magnetic
resonance
(MRI)
provides
resolution
structures
deep
within
body
and,
combination
with
other
modalities,
complementary
diagnostic
information
for
more
accurate
identification
characteristics
precise
guidance
anti-cancer
therapy.
This
review
article
presents
comprehensive
assessment
combine
MRI-based
(T1
MRI,
T2
multimodal
imaging)
therapy
(chemo-,
thermal-,
gene-
therapy),
connecting
range
topics
hybrid
treatment
options
(e.g.
combined
chemo-gene
unique
T1-T2
triple
quadruple
imaging),
novel
strategies
dual
magnetic-active
nanoparticles
carrying
multiple
ligands),
microenvironment-responsive
drug
release
redox
pH-responsive
nanomaterials).
With
special
focus
on
tested
vivo,
this
is
an
essential
summary
most
advanced
developments
rapidly
evolving
field.
European Heart Journal,
Journal Year:
2022,
Volume and Issue:
43(41), P. 4229 - 4361
Published: Aug. 26, 2022
65-74
years,
Sex
category
(female)
CIED
Cardiac
implantable
electronic
device
CML
Chronic
myeloid
leukaemia
CMR
magnetic
resonance
COMPASS-CAT
Prospective
COmparison
of
Methods
for
thromboembolic
European Heart Journal,
Journal Year:
2021,
Volume and Issue:
43(4), P. 280 - 299
Published: Sept. 10, 2021
The
discipline
of
Cardio-Oncology
has
seen
tremendous
growth
over
the
past
decade.
It
is
devoted
to
cardiovascular
(CV)
care
cancer
patient,
especially
mitigation
and
management
CV
complications
or
toxicities
therapies,
which
can
have
profound
implications
on
prognosis.
To
that
effect,
many
studies
assessed
in
patients
undergoing
various
types
therapies;
however,
direct
comparisons
proven
difficult
due
lack
uniformity
toxicity
endpoints.
Similarly,
clinical
practice,
there
be
substantial
differences
understanding
what
constitutes
toxicity,
lead
significant
variation
patient
outcomes.
This
document
addresses
these
issues
provides
consensus
definitions
for
most
commonly
reported
toxicities,
including
cardiomyopathy/heart
failure
myocarditis,
vascular
hypertension,
as
well
arrhythmias
QTc
prolongation.
current
reflects
a
harmonizing
review
landscape
used
define
these.
effort
aims
provide
structure
clinic
future
research.
will
important
link
outlined
herein
outcomes
practice
endpoints
trials.
should
facilitate
communication
across
disciplines
improve
with
diseases.
Journal of Clinical Investigation,
Journal Year:
2021,
Volume and Issue:
131(5)
Published: Feb. 28, 2021
Immune
checkpoint
inhibitors
(ICIs)
have
transformed
the
treatment
of
various
cancers,
including
malignancies
once
considered
untreatable.
These
agents,
however,
are
associated
with
inflammation
and
tissue
damage
in
multiple
organs.
Myocarditis
has
emerged
as
a
serious
ICI-associated
toxicity,
because,
while
seemingly
infrequent,
it
is
often
fulminant
lethal.
The
underlying
basis
myocarditis
not
completely
understood.
While
importance
T
cells
clear,
inciting
antigens,
why
they
recognized,
mechanisms
leading
to
cardiac
cell
injury
remain
poorly
characterized.
issues
underscore
need
for
basic
clinical
studies
define
pathogenesis,
identify
predictive
biomarkers,
improve
diagnostic
strategies,
develop
effective
treatments.
An
improved
understanding
will
provide
insights
into
equilibrium
between
immune
cardiovascular
systems.
Nature Reviews Clinical Oncology,
Journal Year:
2023,
Volume and Issue:
20(8), P. 527 - 542
Published: May 25, 2023
Despite
the
importance
of
chemotherapy-associated
adverse
events
in
oncology
practice
and
broad
range
interventions
available
to
mitigate
them,
limited
systematic
efforts
have
been
made
identify,
critically
appraise
summarize
totality
evidence
on
effectiveness
these
interventions.
Herein,
we
review
most
common
long-term
(continued
beyond
treatment)
late
or
delayed
(following
associated
with
chemotherapy
other
anticancer
treatments
that
pose
major
threats
terms
survival,
quality
life
continuation
optimal
therapy.
These
effects
often
emerge
during
continue
course
therapy
arise
among
survivors
months
years
following
treatment.
For
each
effects,
discuss
evaluate
their
underlying
biological
mechanisms,
commonly
used
pharmacological
non-pharmacological
treatment
strategies,
evidence-based
clinical
guidelines
for
appropriate
management.
Furthermore,
risk
factors
validated
risk-assessment
tools
identifying
patients
likely
be
harmed
by
potentially
benefit
from
effective
Finally,
highlight
promising
emerging
supportive-care
opportunities
ever-increasing
number
cancer
at
continuing
effects.
The
management
treatment-related
remains
an
unmet
need
oncology.
authors
this
Review
factors,
(continuing
treatments.
International Journal of Molecular Sciences,
Journal Year:
2021,
Volume and Issue:
22(17), P. 9118 - 9118
Published: Aug. 24, 2021
Cancer
is
one
of
the
primary
causes
worldwide
human
deaths.
Most
cancer
patients
receive
chemotherapy
and
radiotherapy,
but
these
treatments
are
usually
only
partially
efficacious
lead
to
a
variety
serious
side
effects.
Therefore,
it
necessary
develop
new
therapeutic
strategies.
The
emergence
nanotechnology
has
had
profound
impact
on
general
clinical
treatment.
application
facilitated
development
nano-drug
delivery
systems
(NDDSs)
that
highly
tumor
selective
allow
for
slow
release
active
anticancer
drugs.
In
recent
years,
vehicles
such
as
liposomes,
dendrimers
polymer
nanomaterials
have
been
considered
promising
carriers
tumor-specific
drug
delivery,
reducing
toxicity
improving
biocompatibility.
Among
them,
nanoparticles
(NPs)
most
innovative
methods
non-invasive
delivery.
Here,
we
review
NPs
in
gene
therapy,
early
diagnostics
therapy.
